Neurovalens
PrivateLast Round
Early Funding
Aug 19, 2025
Total Funding Raised
$25.37M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Neurovalens is a health-technology company that develops non-invasive neurostimulation products to address global health issues.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, D2C Brands, Health IoT, Clinical Trials
Business Model
B2C
Customer Profile
Hardware Sales, Subscription SaaS
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neurovalens Comparables
Compare Neurovalens with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Znicz | 85% | |
| Parasym | 79% | |
| Earable Neuroscience | 79% | |
Neurovalens Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Aug 19, 2025 | ||||
| VC Round | Aug 19, 2025 | ||||
| Series A Extension | Apr 8, 2024 | ||||
| Debt | Jan 21, 2022 | ||||
| Grant | Sep 1, 2021 | ||||
VC Round | Jul 20, 2020 |
Key People
Founding team and executive leadership
Neurovalens Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ACF Investors | VC Round, Early Funding |
| MedTech Innovator | Series A Extension |
| Future Fund | VC Round |
| Whiterock Finance | Debt, VC Round, Early Funding |
| British Business Bank | Series A Extension, Series A, Early Funding |
| Invest Northern Ireland | Series A Extension, Grant |
| IQ Capital | VC Round, Series A Extension, Series A, Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 128% MoM.
- Jul 16, 2026
Grew 15% QoQ, from 26 to 30 employees.
Neurovalens Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Neurovalens's valuation, stock price, and market status.